Clinical trials
Lupus clinical trials
Below are recruiting lupus clinical trials, each written for real people, not researchers. We’re tracking 337 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06822881RecruitingPhase 1
Cell therapy for lupus and scleroderma
This trial tests a new cell therapy (CT1190B) for people with moderate to severe lupus or systemic sclerosis that has not responded to standard treatments. The therapy aims to calm the overactive immune system causing these autoimmune diseases.
Beijing, Beijing MunicipalityAges 18–60 - NCT06841042RecruitingPhase 1/Phase 2
Testing a new drug for active lupus
This study tests a new investigational drug called SCTB35 for people with active systemic lupus erythematosus (SLE or lupus). It aims to see if the drug is safe and effective in controlling lupus activity when added to your current stable lupus medications.
BeijingAges 18–75 - NCT06881290RecruitingPhase 1
Vunakizumab for mild to moderate lupus
This trial tests a new drug called Vunakizumab for people with mild to moderate lupus that affects the skin or joints. It aims to see if adding this drug to your current treatment can help control symptoms better.
Beijing, Beijing MunicipalityAges 18–65 - NCT06904729RecruitingPhase 3
CAR-T cell therapy for tough lupus kidney disease in children
This trial tests a new type of immune cell therapy (CAR-T cells) for children whose lupus kidney disease (lupus nephritis) has not responded to standard treatments. The CAR-T cells are designed to target and remove certain immune cells that are attacking the kidneys, with the goal of stopping the disease.
Guangzhou, GuangdongAges 6–18 - NCT06916806RecruitingPhase 1
Study of AZD5492 for lupus, myositis, or rheumatoid arthritis
This trial tests an investigational drug called AZD5492 for people with active lupus, inflammatory myositis, or rheumatoid arthritis who haven't responded well to other treatments. It aims to see if the drug is safe and how it works in the body.
Anniston, AlabamaAges 18–70 - NCT06920433RecruitingEarly Phase 1
Targeted cell therapy for tough lupus with kidney involvement
This early-phase trial tests a special immune cell therapy (UCAR T-cells) that targets two proteins (CD19 and BCMA) on the surface of lupus B cells. It is for people with difficult-to-treat lupus that affects the kidneys (lupus nephritis) who have not gotten better with standard treatments.
Hangzhou, ZhejiangAges 18 years+ - NCT06921239Recruiting
HLA antibodies in lupus patients
This study looks for certain immune markers (HLA antibodies) in stored blood samples from people with lupus. It may help doctors understand how the immune system behaves in lupus.
AmiensAges 18 years+ - NCT06943937RecruitingPhase 1
Cell therapy for hard-to-treat lupus
This trial tests a new type of cell therapy (YTS109 cells) for people with severe lupus that hasn't been controlled by standard treatments. The goal is to see if these cells can help calm the immune system and improve lupus symptoms.
Beijing, Beijing MunicipalityAges 18–65 - NCT07010835RecruitingPhase 1/Phase 2
Study of YK012 for moderate to severe lupus
This trial tests a new drug, YK012, for people with moderate to severe lupus. It aims to see if the drug can reduce disease activity and improve symptoms.
Beijing, Beijing MunicipalityAges 18–75 - NCT07011043RecruitingPhase 1
Study of budoprutug for lupus
This trial tests an investigational drug called budoprutug for people with active systemic lupus erythematosus (SLE) that has not improved after at least two previous treatments. The goal is to see if it can help control lupus symptoms.
Allen, TexasAges 18–65 - NCT07041801RecruitingPhase 1/Phase 2
Stem cell therapy for lupus patients
This trial tests whether a type of stem cell from umbilical cords can help people with systemic lupus erythematosus (an autoimmune disease). It aims to find a new way to reduce lupus symptoms and improve quality of life.
Shenzhen, GuangdongAges 18–65 - NCT07087912RecruitingPhase 4
Dengue vaccine safety in people with autoimmune rheumatic diseases
This study tests the safety and immune response of a dengue vaccine in people aged 12–59 with stable autoimmune rheumatic diseases (like rheumatoid arthritis or lupus) who are on low-dose or no immune-suppressing medications. It also includes healthy volunteers for comparison.
São Paulo, São PauloAges 12–59 - NCT07104721RecruitingPhase 1
YTS109 cell therapy for severe autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity in conditions like lupus, Sjögren's syndrome, and others.
Hefei, AnhuiAges 18–65 - NCT07123519RecruitingPhase 1
YTS109 cell therapy for hard-to-treat autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with certain severe autoimmune diseases that have not responded to standard treatments, such as lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. The goal is to see if it can safely reduce disease activity.
TianjinAges 18–65 - NCT07215663RecruitingPhase 1
Cizutamig for active lupus not helped by other treatments
This study tests a new biologic drug called cizutamig for people with active lupus (SLE) who haven't gotten enough help from standard treatments. The goal is to see if it can safely reduce disease activity.
BeijingAges 18–75 - NCT07215754Recruiting
Real-world study of anifrolumab for active lupus
This study tracks how well anifrolumab works and how safe it is for people with active lupus. It's a real-world look at the drug's effects, so no additional treatments or tests are required beyond what your doctor already prescribes.
PisaAges 18 years+ - NCT07225387RecruitingPhase 4
Belimumab and voclosporin for lupus kidney disease
This study tests whether combining two medications, belimumab and voclosporin, is safe and effective for treating a specific type of lupus that affects the kidneys (lupus nephritis). It may help people with active kidney inflammation who need better control of their disease.
Glendale, ArizonaAges 18–80 - NCT07225543RecruitingPhase 2
Study of 2-HOBA for women with lupus
This trial tests whether a natural compound called 2-HOBA can help women with lupus who also have mildly high blood pressure. It aims to improve blood vessel health and reduce inflammation.
Nashville, TennesseeAges 18 years+ - NCT07236762RecruitingPhase 1
YTS109 cell therapy for severe autoimmune diseases
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases like lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. It's for those whose disease hasn't improved with standard treatments.
BengbuAges 18–65 - NCT07260942Recruiting
Study of ferroptosis in lupus
This study looks at whether a type of cell death called ferroptosis plays a role in lupus. Participants with lupus or with rheumatoid arthritis or inflammatory bowel disease will be compared to understand more about how lupus works.
BordeauxAges 18 years+ - NCT07282392Recruiting
Emotional awareness therapy for lupus and fibromyalgia pain
This study tests if a therapy called Emotional Awareness and Expression Therapy (EAET) can help people with lupus and fibromyalgia or chronic widespread pain feel better by addressing emotional factors that may worsen their pain. You would attend sessions to learn how to understand and express your emotions in healthy ways.
Salt Lake City, UtahAges 18–65 - NCT07299422RecruitingPhase 2
Study of SHR-2173 for people with lupus
This trial tests a new drug called SHR-2173 for people with active lupus. It aims to see if it can reduce disease activity when taken with standard treatments.
Beijing, Beijing MunicipalityAges 18–65 - NCT07313475Recruiting
Testing a new tool to detect lupus anticoagulant
This trial checks if a new method (Cryocheck HexLA Integrated TCA) can accurately find lupus anticoagulant in blood samples. Your leftover blood from regular tests may be used, and it requires no extra visits.
StrasbourgAges 18 years+ - NCT07323173RecruitingPhase 1
Testing LBL-047 in healthy adults and lupus patients
This study tests a new drug called LBL-047 in healthy volunteers and in people with mild-to-moderate lupus. The goal is to see if it is safe and how the body handles it.
Bengbu, AnhuiAges 18–60
Hear when a new Lupus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lupus?
- Yes. Clin2 currently lists 337 recruiting lupus studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lupus trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lupus trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.